Gene therapy had banner year in 2017 with 164% funding boost to $4.5 billion

Calling 2017 a “banner year for regenerative and advanced therapies,” the Alliance for Regenerative Medicine (ARM) reported Monday that gene and gene-modified cell therapy saw a 164 percent funding bump in 2017 compared to 2016, to the tune of $4.5 billion for the sector. The 2017 Annual Data Report from the group also found a 78.5 percent leap in global funding for regenerative medicine overall to more than $7.5 billion in 2017 as well as 946 clinical trials underway in 2017.  It called the Food and Drug Administration approvals of regenerative medicine-related therapies “historic.” The approvals include those for the CAR T-cell therapies...

Read More